| # | Drug | Count |
|---|---|---|
| 0 | ASPIRIN | 60 |
| 1 | ASPIRIN 325 MG | 59 |
| 2 | ASPIRIN 81 MG | 59 |
| 3 | PACLITAXEL | 57 |
| 4 | PACLITAXEL (AIBUMIN-BOUND) | 57 |
| 5 | CYCLOPHOSPHAMIDE | 54 |
| 6 | CYCLOPHOSPHAMIDE FOR INJECTION | 54 |
| 7 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 54 |
| 8 | DOXORUBICIN | 44 |
| 9 | SPIRONOLACTONE | 44 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | COCAINE HYDROCHLORIDE NASAL | 2 | 0.0308 |
| 1 | ASIAN GINSENG | 2 | 0.0047 |
| 2 | DEXRAZOXANE FOR INJECTION | 4 | 0.0042 |
| 3 | ESOMEPRAZOLE SODIUM | 8 | 0.0033 |
| 4 | MAVACAMTEN | 16 | 0.0026 |
| 5 | ANAGRELIDE HYDROCHLORIDE | 2 | 0.0017 |
| 6 | LEVOLEUCOVORIN | 6 | 0.0016 |
| 7 | FAM-TRASTUZUMAB DERUXTECAN-NXKI | 14 | 0.0013 |
| 8 | ALECTINIB HYDROCHLORIDE | 8 | 0.0011 |
| 9 | PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF | 5 | 0.0010 |
| # | Drug class | Count |
|---|---|---|
| 0 | Nonsteroidal Anti-inflammatory Drug [EPC] | 82 |
| 1 | Corticosteroid [EPC] | 71 |
| 2 | Platinum-based Drug [EPC] | 68 |
| 3 | Microtubule Inhibitor [EPC] | 64 |
| 4 | Alkylating Drug [EPC] | 62 |
| 5 | Platelet Aggregation Inhibitor [EPC] | 60 |
| 6 | Sodium-Glucose Cotransporter 2 Inhibitor [EPC] | 54 |
| 7 | Aldosterone Antagonist [EPC] | 50 |
| 8 | Factor Xa Inhibitor [EPC] | 50 |
| 9 | Loop Diuretic [EPC] | 50 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Melanocortin 4 Receptor Agonist [EPC] | 1 | 0.0035 |
| 1 | Interleukin-5 Antagonist [EPC] | 2 | 0.0029 |
| 2 | Endoglycosidase [EPC] | 5 | 0.0027 |
| 3 | Cardiac Myosin Inhibitor [EPC] | 16 | 0.0026 |
| 4 | CD38-directed Cytolytic Antibody [EPC] | 5 | 0.0009 |
| 5 | Provitamin D2 Compound [EPC] | 22 | 0.0007 |
| 6 | Chemokine Receptor Type 4 Interaction [EPC] | 1 | 0.0007 |
| 7 | Plasma Volume Expander [EPC] | 2 | 0.0006 |
| 8 | Phosphodiesterase 3 Inhibitor [EPC] | 4 | 0.0006 |
| 9 | Cytomegalovirus DNA Terminase Complex Inhibitor [EPC] | 2 | 0.0006 |